ライフサイエンスコーパス: oophorectomy

1 , and previous hysterectomy (with or without oophorectomy).

2 in the same population who had not undergone oophorectomy.

3 he efficacy of prophylactic hysterectomy and oophorectomy.

4 are these with women who had not received an oophorectomy.

5 rospectively for breast cancer incidence and oophorectomy.

6 not undergone hysterectomy, with or without oophorectomy.

7 dy participants were censored at the time of oophorectomy.

8 e that developed in women after menopause or oophorectomy.

9 from 3.34 to 4.65 years, depending on age at oophorectomy.

10 iestrogen therapy, i.e., progesterone and/or oophorectomy.

11 , irrespective of whether HRT was used after oophorectomy.

12 undergoing both prophylactic mastectomy and oophorectomy.

13 e of hormone replacement therapy (HRT) after oophorectomy.

14 8 and 8.6 years after bilateral prophylactic oophorectomy.

15 for ovarian cancer or risk-reducing salpingo-oophorectomy.

16 horectomy and 55 with a concurrent bilateral oophorectomy.

17 as adjusted for age, smoking, and unilateral oophorectomy.

18 bilateral mastectomies and 68%, prophylactic oophorectomy.

19 bdominal hysterectomy and bilateral salpingo-oophorectomy.

20 develop in a woman years after prophylactic oophorectomy.

21 th total hysterectomy and bilateral salpingo-oophorectomy.

22 g surgery in the form of unilateral salpingo-oophorectomy.

23 procedures, ie, bilateral mastectomy and/or oophorectomy.

24 ecular bone sustained by rats within 6 wk of oophorectomy.

25 t of premenopausal women underwent bilateral oophorectomy.

26 1-3.45; P < .001) compared with no bilateral oophorectomy.

27 ompared to 62% for women who did not have an oophorectomy.

28 ompared to 28% for women who did not have an oophorectomy.

29 ephrectomy; 134985, hysterectomy; and 27445, oophorectomy.

30 ed for women who did and who did not undergo oophorectomy.

31 106 women had a hysterectomy with bilateral oophorectomy.

32 ucocele 2 years after risk-reducing salpingo-oophorectomy.

33 1 mutation, survival was much improved after oophorectomy.

34 undergone a hysterectomy with or without an oophorectomy.

35 prior hormone-sensitive cancers or bilateral oophorectomy.

36 at menopause, or history of hysterectomy or oophorectomy.

37 to have mastectomies and 33% (4/12) to have oophorectomies.

38 047 (10.4%) hysterectomies, and 1782 (6.5%) oophorectomies.

39 (95% CI, 1.34-1.50) after oophorectomy vs no oophorectomy, 0.88 (95% CI, 0.85-0.90) after hysterectom

40 compared with not having had a hysterectomy/oophorectomy (1.51; 1.34-1.71).

41 1293 women with unilateral oophorectomy, 1097 with bilateral oophorectomy, and 2390

42 Six women who underwent prophylactic oophorectomy (2.3 percent) received a diagnosis of stage

43 Among premenopausal women who had unilateral oophorectomy, 21 percent were on HRT at 3 months, increa

44 6 years with both tamoxifen and prophylactic oophorectomy, 3.5 years with prophylactic mastectomy, an

45 en seen at our clinic underwent prophylactic oophorectomy, 33 of whom had a calculated risk of carryi

46 with tamoxifen, 2.6 years with prophylactic oophorectomy, 4.6 years with both tamoxifen and prophyla

47 ad undergone prophylactic bilateral salpingo-oophorectomy (47 women) were matched with mutation-posit

48 with tamoxifen, 4.4 years with prophylactic oophorectomy, 6.3 years with tamoxifen and oophorectomy,

49 with BRCA1/2 mutations undergo prophylactic oophorectomy after completion of childbearing, decide ab

50 Of the 676 women, 345 underwent oophorectomy after the diagnosis of breast cancer and 33

51 s, with and without quality adjustment, were oophorectomy alone and oophorectomy and mastectomy, resp

52 an incremental cost-effectiveness ratio over oophorectomy alone of 2352 dollars per life-year for BRC

53 The increased rate of oophorectomy among mutation carriers suggests that testi

54 The QALYs saved were 0.5 for oophorectomy and 1.9 for the combined procedures in the

55 omy: 42 without oophorectomy or a unilateral oophorectomy and 55 with a concurrent bilateral oophorec

56 ately 4 years with hysterectomy and salpingo-oophorectomy and adherence to colorectal cancer screenin

57 ort studies, the Mayo Clinic Cohort Study of Oophorectomy and Aging 1 and 2, which were based on the

58 ng data from the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 for a population in Olmsted Cou

59 ptibility genes BRCA1 or BRCA2, prophylactic oophorectomy and bilateral mastectomy have emerged as pr

60 h prior or concurrent bilateral prophylactic oophorectomy and by approximately 90% in women with inta

61 and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy,

62 on at baseline between years since bilateral oophorectomy and common carotid artery intima-media thic

63 on-based sample of women who had received an oophorectomy and compare these with women who had not re

64 plained by greater frequency of hysterectomy/oophorectomy and earlier age at surgery after endometrio

65 women, 31 to 56 years old, who had undergone oophorectomy and hysterectomy received conjugated equine

66 history of premenopausal surgery, bilateral oophorectomy and hysterectomy without oophorectomy were

67 In women who have undergone oophorectomy and hysterectomy, transdermal testosterone

68 men who had undergone bilateral prophylactic oophorectomy and in 142 matched controls.

69 men who had undergone bilateral prophylactic oophorectomy and in 292 matched controls who had not und

70 lity adjustment, were oophorectomy alone and oophorectomy and mastectomy, respectively.

71 idates for risk reduction strategies such as oophorectomy and mastectomy.

72 ures (including a laparotomy and at least an oophorectomy and omental biopsy) in each group of the st

73 2 testing on the utilization of prophylactic oophorectomy and ovarian cancer screening.

74 gen replacement therapy (ERT), or history of oophorectomy and pancreatic cancer.

75 he 98 women who chose risk-reducing salpingo-oophorectomy and peritoneal cancer was diagnosed in 1 wo

76 tisite randomized clinical trial of adjuvant oophorectomy and tamoxifen for 5 years or observation an

77 in a randomized controlled trial of adjuvant oophorectomy and tamoxifen or observation who had estrog

78 may favorably influence response to adjuvant oophorectomy and tamoxifen treatment in patients with es

79 re significantly improved following adjuvant oophorectomy and tamoxifen.

80 enefit from adjuvant treatment with surgical oophorectomy and tamoxifen.

81 9 women who underwent bilateral prophylactic oophorectomy and who were studied to determine the risk

82 We excluded women who had hysterectomy or oophorectomy and women who did not report their age at m

83 Salpingo-oophorectomy and/or mastectomy are currently the only ef

84 e menopause (menopause before age 40 without oophorectomy) and surgical premature menopause (bilatera

85 c oophorectomy, 6.3 years with tamoxifen and oophorectomy, and 2.6 years with mastectomy, or with bot

86 unilateral oophorectomy, 1097 with bilateral oophorectomy, and 2390 referent women were eligible for

87 (95% probability interval, 4 to 25 days) for oophorectomy, and 6 days (95% probability interval, 3 to

88 bdominal hysterectomy and bilateral salpingo-oophorectomy, and administration of six cycles of intrav

89 cologic procedures including tubal ligation, oophorectomy, and partial hysterectomy have been demonst

90 aparoscopic hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy revealed Intern

91 es (cholecystectomy, colectomy, hysterectomy/oophorectomy, and prostatectomy) between 1987 and 2004.

92 bout effects of HRT, effects of prophylactic oophorectomy, and risks of cancer associated with BRCA1/

93 and/or amenorrhea lasting >6 months, and/or oophorectomy, and/or increased follicle-stimulating horm

94 ," "preventive," "bilateral," "mastectomy," "oophorectomy," and "ovariectomy," a MEDLINE search of th

95 n including hysterectomy, bilateral salpingo-oophorectomy, appendectomy, resection of pelvic tumor, o

96 Cohort studies suggest that women with oophorectomy are at greater risk for CHD than intact wom

97 hat women who undergo prophylactic bilateral oophorectomy are at increased risk of death for all caus

98 ancer risk reductions conferred by bilateral oophorectomy are not strongly confounded by failure to a

99 Prophylactic mastectomy and oophorectomy are often considered as ways of reducing th

100 Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRC

101 ctomy, partial nephrectomy, hysterectomy, or oophorectomy at 1370 hospitals in the United States from

102 Among women who underwent oophorectomy at 45 years and younger, the risk was lower

103 men (2679 White [97.4%]) underwent bilateral oophorectomy at a median age of 45.0 years (IQR, 40.0-48

104 to age 75 years was 14% for women who had an oophorectomy at age 35 years compared to 28% for women w

105 rtality to age 75 years for women who had an oophorectomy at age 35 years was 25%, compared to 62% fo

106 nd salpingectomy at age 40 years and delayed oophorectomy at age 50 years [hyst-BS]) was included.

107 ldbearing, decide about short-term HRT after oophorectomy based largely on quality-of-life issues rat

108 cted on women who had undergone prophylactic oophorectomies because of the elevated risk of ovarian c

109 and surgical premature menopause (bilateral oophorectomy before age 40).

110 Bilateral oophorectomy before menopause and before age 46 years wa

111 omen who had received prophylactic bilateral oophorectomy before the age of 45 years than in referent

112 Therefore, women who underwent bilateral oophorectomy before the onset of menopause or women who

113 f-reported receipt of bilateral prophylactic oophorectomy (BPO) and utilization of CA-125 and transva

114 Bilateral prophylactic oophorectomy (BPO) is widely used for cancer risk reduct

115 onsider the option of bilateral prophylactic oophorectomy (BPO), in the hope that removal of healthy

116 Bilateral prophylactic salpingo-oophorectomy (BPSO) is used widely used to reduce the ri

117 cember 31, 2017 (n = 825 238), without prior oophorectomy, breast cancer, or cancer in reproductive o

118 en women with and without bilateral salpingo-oophorectomy (BSO) is unknown.

119 ons between hysterectomy, bilateral salpingo-oophorectomy (BSO), and incidence of diabetes in postmen

120 omy, by 2.8 to 3.4 years; and mastectomy and oophorectomy, by 3.3 to 6.0 years over surveillance.

121 n women with a BRCA1 or BRCA2 mutation after oophorectomy, by age of oophorectomy; to estimate the im

122 he onset of ENM, age 45 years, hysterectomy, oophorectomy, cancer diagnosis, death, loss to follow-up

123 age or older who had not undergone bilateral oophorectomy chose to undergo either surveillance for ov

124 ween January 1, 1950, and December 31, 2007 (oophorectomy cohort), and 2749 age-matched women who did

125 t increased in women who underwent bilateral oophorectomy compared with referent women.

126 breast cancer risk associated with bilateral oophorectomy could be affected by common conditions that

127 was ignored, the strong protective effect of oophorectomy, coupled with the high prevalence of the pr

128 omen without surgery; risk-reducing salpingo-oophorectomy decreased breast cancer incidence by 37% to

129 Oophorectomy decreased the splenic homing, autoantibody

130 at premenopausal hysterectomy with bilateral oophorectomy decreases the risk of breast cancer in blac

131 7 years of life expectancy from prophylactic oophorectomy, depending on their cumulative risk of canc

132 In contrast, although oophorectomy did not significantly influence rAAV transd

133 With quality adjustment, oophorectomy dominated all other strategies for BRCA1 an

134 of this algorithm might prevent unnecessary oophorectomy during adolescence and its lifelong consequ

135 the 33 mutation-positive women who underwent oophorectomy during follow-up developed breast cancer, c

136 Prophylactic mastectomy and prophylactic oophorectomy, effective in retrospective clinical experi

137 rst birth, oral contraceptive use, bilateral oophorectomy, estrogen plus progestin use, and height.

138 ed; of those, 2750 women underwent bilateral oophorectomy for a benign indication before spontaneous

139 50-87, we analysed those who had received an oophorectomy for a non-cancer indication before the onse

140 ce surgical menopause following hysterectomy/oophorectomy for noncancerous conditions; it is also com

141 as young BRCA1/2 carriers with prophylactic oophorectomy for ovarian cancer prevention.

142 rning the efficacy of bilateral prophylactic oophorectomy for reducing the risk of gynecologic cancer

143 dentified through risk-reducing prophylactic oophorectomy from three women with germline BRCA1 mutati

144 ause, and cancer treatments such as surgical oophorectomy, gonadotropin-releasing hormone agonists, c

145 years since hysterectomy in the no bilateral oophorectomy group (beta = 0.005 (standard error, 0.023)

146 ynecologic cancer was longer in the salpingo-oophorectomy group, with a hazard ratio for subsequent b

147 terectomy by about a fourth in the bilateral oophorectomy group.

148 o-oophorectomy, women who underwent salpingo-oophorectomy had a lower risk of ovarian cancer, includi

149 Oophorectomy had no effect on renal EGFR levels in femal

150 eries (prophylactic bilateral mastectomy and oophorectomy) had an incremental cost-effectiveness rati

151 nd ovarian cancer, but it is unclear whether oophorectomy has an impact on survival in women with BRC

152 Prophylactic salpingo-oophorectomy has been demonstrated to decrease the risk

153 ered after randomisation to have a bilateral oophorectomy, have ovarian cancer, or had exited the reg

154 served (HOC), or hysterectomy with bilateral oophorectomy (HBSO).

155 nal hypertension for hemorrhagic stroke, and oophorectomy, HDP, preterm delivery, and stillbirth for

156 ween women who underwent hysterectomy and/or oophorectomy (higher odds for less educated women) and t

157 last births, age at menopause, hysterectomy, oophorectomy, hormone therapy use, and body mass index (

158 onic kidney disease, hysterectomy, bilateral oophorectomy, hormone therapy, infertility treatment, en

159 liparity (HR 2.14, P = 0.01), and unilateral oophorectomy (HR 6.51, P < 0.0001).

160 s of age (HR 2.36, P = 0.01), and unilateral oophorectomy (HR 9.76, P < 0.0001) were independent dete

161 risk of PD in women younger than 43 years at oophorectomy (HR, 5.00; 95% CI, 1.10-22.70), with a numb

162 -2.46) and in women younger than 43 years at oophorectomy (HR, 7.67; 95% CI, 1.77-33.27).

163 aried at hysterectomy and bilateral salpingo-oophorectomy (hyst-BSO) and at surveillance initiation,

164 ure, including age at bilateral prophylactic oophorectomy if applicable.

165 hylactic hysterectomy; and 52%, prophylactic oophorectomy if they tested positive for a mutation.

166 according to her cancer risks, prophylactic oophorectomy improved survival by 0.4 to 2.6 years; mast

167 Among women who had undergone bilateral oophorectomy, IMT was significantly related to years sin

168 Salpingo-oophorectomy in carriers of BRCA mutations can decrease

169 s recorded in women who underwent unilateral oophorectomy in either overall or stratified analyses.

170 the efficacy of prophylactic mastectomy and oophorectomy in preventing breast and ovarian cancer to

171 oncology but may be useful for prophylactic oophorectomy in selected individuals.

172 The benefits of oophorectomy in this setting are unknown, and the proced

173 nancies detected after prophylactic salpingo-oophorectomy in women with BRCA mutations.

174 hylactic hysterectomy and bilateral salpingo-oophorectomy in women with the Lynch syndrome.

175 ylactic hysterectomy with bilateral salpingo-oophorectomy is an effective strategy for preventing end

176 Oophorectomy is associated with a decrease in mortality

177 Oophorectomy is commonly performed in premenopausal wome

178 Preventive salpingo-oophorectomy is currently the only method known to reduc

179 The decision about prophylactic oophorectomy is difficult for many premenopausal women w

180 RCA1/2 carriers after risk-reducing salpingo-oophorectomy is highly likely the appendix.

181 Risk-reducing salpingo-oophorectomy is often considered by carriers of BRCA mut

182 Bilateral oophorectomy is often performed during hysterectomy for

183 Preventive bilateral salpingo-oophorectomy is recommended to women with a BRCA mutatio

184 In our model, prophylactic oophorectomy lengthened life expectancy in women with BR

185 Differing rates of oophorectomy likely represent an underappreciated basis

186 After bilateral oophorectomy, many women report impaired sexual function

187 fen, oral contraceptives, bilateral salpingo-oophorectomy, mastectomy, both surgeries, or surveillanc

188 cer pathogenesis, salpingectomy with delayed oophorectomy may be a novel risk-reducing strategy with

189 novel 2-stage surgical approach with delayed oophorectomy may be an alternative to hyst-BSO at age 40

190 Among 30-year-old women, oophorectomy may be delayed 10 years with little loss of

191 age, a more conservative unilateral salpingo-oophorectomy may be performed, assuming that careful sta

192 ysterectomy status with or without bilateral oophorectomy might increase risk for CVD, but most studi

193 al gains in life expectancy and prophylactic oophorectomy more limited gains for young women with BRC

194 h lower odds of breast cancer (for bilateral oophorectomy, multivariable-adjusted odds ratios = 0.60,

195 terval: 0.47, 0.77; for hysterectomy without oophorectomy, multivariable-adjusted odds ratios = 0.68,

196 primary hysterectomy and bilateral salpingo-oophorectomy, often using minimally invasive approaches

197 is surgery (hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy), followe

198 f removing endogenous estrogen, we performed oophorectomies on Pten(+/-) mice.

199 tomy; to estimate the impact of prophylactic oophorectomy on all-cause mortality; and to estimate 5-y

200 apy reverses the adverse effect of bilateral oophorectomy on coronary heart disease.

201 viduals who underwent risk-reducing salpingo-oophorectomy, one early-stage ovarian neoplasm and one e

202 en women reported a hysterectomy: 42 without oophorectomy or a unilateral oophorectomy and 55 with a

203 70 female participants, without a history of oophorectomy or cancer, 1234 epithelial ovarian cancer c

204 We excluded participants who had a bilateral oophorectomy or conditions that were contraindicated in

205 in the smaller group of women with bilateral oophorectomy or hysterectomy with one ovary retained.

206 sociated with breast cancer risk, but either oophorectomy or hysterectomy, or both, and the timing of

207 Exclusion criteria were previous bilateral oophorectomy or ovarian malignancy, increased risk of fa

208 o patient in the genetic group had undergone oophorectomy or was taking prophylactic agents such as t

209 sing hormone analogue triptorelin, bilateral oophorectomy, or bilateral ovarian irradiation were used

210 ropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation.

211 gnant tumor are not uncommon in prophylactic oophorectomies performed in women at very high risk for

212 r of women experience early menopause due to oophorectomy performed for benign indications.

213 my (PM) at various ages, and/or prophylactic oophorectomy (PO) at ages 40 or 50 years in 25-year-old

214 hylactic mastectomy (PM) and/or prophylactic oophorectomy (PO) at various ages.

215 hypothesized that population differences in oophorectomy prevalence might significantly influence br

216 ncy or cancer prevention through castration (oophorectomy), preventing chemically induced mouse carci

217 tic ovary syndrome, endometriosis, bilateral oophorectomy, previous or ongoing medication with hormon

218 Exclusion criteria were bilateral oophorectomy, previous ovarian or active non-ovarian mal

219 e investigated whether prophylactic salpingo-oophorectomy (PSO) for patients with previously resected

220 Oophorectomy reduced renal medullary eNOS levels to that

221 Oophorectomy reduced renal medullary iNOS levels to that

222 Because prophylactic oophorectomy reduces breast cancer risk by approximately

223 Bilateral prophylactic oophorectomy reduces the risk of coelomic epithelial can

224 bdominal hysterectomy and bilateral salpingo-oophorectomy revealed similar estimates (HR, 0.59; 95% C

225 Risk-reducing bilateral salpingo-oophorectomy (RRBSO) and risk-reducing mastectomy are wi

226 cost-effectiveness of risk-reducing salpingo-oophorectomy (RRSO) and, where relevant, risk-reducing m

227 Risk-reducing salpingo-oophorectomy (RRSO) has been widely adopted as a key com

228 Risk-reducing salpingo-oophorectomy (RRSO) is effective in decreasing risks of

229 Therefore, although risk-reducing salpingo-oophorectomy (RRSO) is standard treatment among women wi

230 Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal

231 Risk-reducing salpingo-oophorectomy (RRSO) was encouraged throughout the study.

232 After risk-reducing salpingo-oophorectomy (RRSO), BRCA1/2 pathogenic variant (PV) car

233 s risk reduction from risk-reducing salpingo-oophorectomy (RRSO), by CJM and self-identified Jewish s

234 duction, particularly risk-reducing salpingo-oophorectomy (RRSO), has become an important component o

235 ngly choose bilateral risk-reducing salpingo-oophorectomy (RRSO).

236 t cancer and a BRCA1 mutation should undergo oophorectomy shortly after diagnosis.

237 ting for time-varying hysterectomy/bilateral oophorectomy showed no association between use of hormon

238 ancer was diagnosed at surgery, prophylactic oophorectomy significantly reduced the risk of coelomic

239 lated tumor predisposition, and explains why oophorectomy significantly reduces breast cancer risk an

240 s of these mutations, risk-reducing salpingo-oophorectomy significantly reduces morbidity and mortali

241 rian cancer, prophylactic bilateral salpingo-oophorectomy significantly reduces the incidence of this

242 een determined; however, estrogen reduction (oophorectomy) significantly reduces recurrence in premen

243 st birth, age at menarche, age at menopause, oophorectomy, smoking, and education.

244 assess the association between hysterectomy/oophorectomy status and diabetes incidence.

245 No study has taken oophorectomy status into account in estimating penetranc

246 Women with a hysterectomy (regardless of oophorectomy status) had an adverse risk profile at base

247 Hysterectomy (regardless of oophorectomy status) was a significant predictor of CVD

248 we observed that hysterectomy, regardless of oophorectomy status, was associated with increased risk

249 ty in women and may vary by hysterectomy (or oophorectomy) status.

250 nalysis of ovarian tissues from prophylactic oophorectomies, suggest that depletion of ovarian follic

251 ratification by indication for the bilateral oophorectomy, there was an increased risk of restless le

252 gainst prophylactic surgery (eg, mastectomy, oophorectomy); these surgeries are an option for mutatio

253 -cause mortality associated with a bilateral oophorectomy (time dependent).

254 carriers are offered risk-reducing salpingo-oophorectomy to reduce their ovarian cancer risk and mag

255 on, or risk-reducing mastectomy and salpingo-oophorectomy, to reduce cancer risk.

256 BRCA2 mutation after oophorectomy, by age of oophorectomy; to estimate the impact of prophylactic oop

257 n who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy was assoc

258 Although prophylactic bilateral oophorectomy undertaken before age 45 years is associate

259 with breast conservation surgery who undergo oophorectomy versus sporadic controls.

260 y stroke were 1.42 (95% CI, 1.34-1.50) after oophorectomy vs no oophorectomy, 0.88 (95% CI, 0.85-0.90

261 peritoneal cancer associated with bilateral oophorectomy was 0.20 (95% CI, 0.13 to 0.30; P < .001).

262 mortality to age 70 years associated with an oophorectomy was 0.23 (95% CI, 0.13 to 0.39; P < .001).

263 uted to breast cancer in women who underwent oophorectomy was 0.38 (95% CI, 0.19-0.77; P = .007) for

264 Bilateral oophorectomy was also associated with an increased risk

265 breast cancer mortality (1 study; n = 639); oophorectomy was associated with 69% to 100% reduction i

266 isk of breast cancer; risk-reducing salpingo-oophorectomy was associated with a lower risk of ovarian

267 Preventive oophorectomy was associated with an 80% reduction in the

268 Bilateral oophorectomy was associated with an increased risk of pa

269 Hysterectomy/oophorectomy was associated with higher risk of CHD and

270 Having had a hysterectomy/oophorectomy was associated with higher risk of combined

271 Oophorectomy was associated with improved survival in BR

272 use, the finding that years since bilateral oophorectomy was associated with increasing atherosclero

273 g salpingo-oophorectomy, undergoing salpingo-oophorectomy was associated with lower all-cause mortali

274 Use of HRT after oophorectomy was associated with relatively small change

275 Hysterectomy with oophorectomy was associated with significantly lower tes

276 idence of IBTR in carriers who had undergone oophorectomy was not significantly different from that i

277 equence variations, information on bilateral oophorectomy was obtained via biennial questionnaire.

278 k demonstrated that the protective effect of oophorectomy was strongest among women who were premenop

279 ility for XFG, surgical menopause (bilateral oophorectomy) was inversely associated with XFG/XFGS com

280 ter severity of lung disease, menopause, and oophorectomy were associated with greater decline in BMD

281 ateral oophorectomy and hysterectomy without oophorectomy were associated with lower odds of breast c

282 ence and all-cause mortality associated with oophorectomy were evaluated using time-dependent surviva

283 ho did not have previous cancer or bilateral oophorectomy were followed-up for an average of 5.3 year

284 re postmenopausal or who underwent bilateral oophorectomy were less likely to have hot flashes if the

285 -matched women who did not undergo bilateral oophorectomy were randomly sampled from the general popu

286 ctor of IBTR when carriers who had undergone oophorectomy were removed from analysis (HR, 1.99; P = .

287 dolescents are benign, many are managed with oophorectomy, which may be unnecessary and can have life

288 women who underwent unilateral or bilateral oophorectomy while residing in Olmsted County, MN, USA,

289 sociations of premenopausal hysterectomy and oophorectomy with breast cancer risk.

290 ship of risk-reducing mastectomy or salpingo-oophorectomy with cancer outcomes.

291 A 36-year-old woman underwent a right oophorectomy with cryopreservation of ovarian cortical s

292 Women who underwent bilateral oophorectomy with hysterectomy at age </= 40 years had s

293 apy; 15 916 (7126 [44.8%] aged 41-50 years), oophorectomy with hysterectomy; and 776 (327 [42.1%] age

294 red prophylactic mastectomy and prophylactic oophorectomy with no prophylactic surgery among women wh

295 comparison of women who underwent bilateral oophorectomy with referent women provided evidence for a

296 ompared the effect of risk-reducing salpingo-oophorectomy with that of surveillance for ovarian cance

297 after hysterectomy with or without bilateral oophorectomy with the changes observed up to and after n

298 -Meier curves to compare women who underwent oophorectomy with those who had ovarian preservation.

299 n who did not undergo risk-reducing salpingo-oophorectomy, women who underwent salpingo-oophorectomy

300 %, respectively, that bilateral prophylactic oophorectomy would reduce ovarian cancer risk by 45%, an